In this edition of STAT Health Tech, we delve into a prominent study evaluating AI's ability to outperform doctors in diagnostic accuracy. Additionally, we explore how telehealth is influencing abortion access and review the ongoing lawsuit involving Epic Systems.
AstraZeneca is set to expand its research and development operations in the UK, benefiting from provisions in the latest US-UK trade agreement that aim to boost UK drug spending. This move underscores the positive impact of international trade deals on pharmaceutical investment and innovation in the region.
On Thursday, scientists reported in the journal Science the findings from a study evaluating an OpenAI model's capacity to perform diagnostic and clinical reasoning tasks. The results showcased impressive capabilities, prompting the scientific community to consider the implications and next steps for integrating AI in healthcare diagnostics.
A newly released report details notable progress in closing health disparities across various U.S. states from 2022 to 2024. Despite these encouraging developments, experts express concern that the gains may not be maintained long-term without sustained effort and policy support.
FDA Commissioner announced a groundbreaking shift in clinical trials: regulators will now monitor trial endpoints live via the cloud. This real-time insight promises to make the drug development process faster and more responsive.
In this STAT Health Tech issue, hospitals are unveiling their own chatbots as a response to ChatGPT's popularity. Additionally, the Medicare ACCESS pilot program is underway, aiming to improve care accessibility. Meanwhile, Utah advances its pioneering 'AI doctor' project, pushing the boundaries of artificial intelligence in healthcare.
For many years, venture capitalists in biotech have depended on a well-established formula to generate profits through drug development. However, this reliable method is now being challenged by rapid changes in the industry, forcing investors to adapt to new trends and uncertainties.
Behind closed doors, health insurers and hospitals acknowledge that AI scribes are driving up healthcare expenses. However, they remain divided on how to address this growing financial challenge.
A small biotech company has been compelled to begin winding down its operations after the FDA unexpectedly postponed a critical meeting by four months. This delay has significant implications for the company's progress and highlights challenges within regulatory timelines. Meanwhile, Neurocrine Biosciences announced a new deal, signaling ongoing activity in the biotech sector despite setbacks faced by smaller players.
The FDA has given the green light to Eli Lilly's latest obesity medication, positioning it in direct rivalry with Novo Nordisk's recently launched Wegovy pill.